BIAXIN

Compare BIAXIN  to:
Compare
Compare

Generic Name for BIAXIN

Clarithromycin 250mg, 500mg; tabs.

Legal Classification:

Rx

Pharmacological Class for BIAXIN

Macrolide.

Manufacturer of BIAXIN

Abbott Laboratories

Indications for BIAXIN

Mild to moderate susceptible pharyngitis/tonsillitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, acute maxillary sinusitis, acute otitis media, uncomplicated skin and skin structure infections. Disseminated M. intracellulare. Treatment (with other antimycobacterials) and prophylaxis of disseminated Mycobacterium avium complex (MAC).

Adult dose for BIAXIN

Pharyngitis/tonsillitis: 250mg every 12 hours for 10 days. Bronchitis: 250mg–500mg every 12 hours for 7–14 days. CAP, skin and skin structures: 250mg every 12 hours for 7–14 days. Sinusitis: 500mg every 12 hours for 14 days. MAC: 500mg every 12 hours continue indefinitely if improvement occurs. CrCl <30mL/min: ½ dose or double dosing interval.

Children's dosing for BIAXIN

<6 months: not recommended. Otitis media, pharyngitis/tonsillitis, pneumonia, sinusitis, skin and skin structures: 7.5mg/kg every 12 hours for 10 days. MAC (see literature): 7.5mg/kg every 12 hours; max 500mg twice daily, continue indefinitely if improvement occurs. CrCl <30mL/min: ½ dose or double dosing interval.

Also:

Contraindications for BIAXIN

Concomitant cisapride, pimozide.

Warnings/Precautions for BIAXIN

Severe renal impairment. Pregnancy (Cat.C): usually not recommended. Nursing mothers.

Interactions for BIAXIN

See Contraindications. May potentiate theophylline, carbamazepine, omeprazole, phenytoin, digoxin, warfarin, ergot alkaloids, triazolam, cyclosporine, hexobarbital, tacrolimus, alfentanil, disopyramide, bromocriptine, valproate, rifabutin, statins; monitor these and others metabolized by CYP450. May affect zidovudine levels. With ritonavir in renal impairment: reduce clarithromycin dose (see literature).

Adverse Reactions for BIAXIN

GI upset, abnormal taste, headache, rash, increased BUN.

How is BIAXIN supplied?

XL tabs, tabs—60
Biaxin XL-Pac (14 x 500mg XL tabs)—4
Susp—50mL, 100mL

Related Disease:

Infections, bacterial~systemic antiinfectives
Pneumonia

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions